EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

Eligibility for Lecanemab Treatment in the Republic of Korea: Real-World Data From Memory Clinics

Sung Hoon Kang iD, Jee Hyang Jeong iD, Jung-Min Pyun iD, Geon Ha Kim iD, Young Ho Park iD, YongSoo Shim iD, Seong-Ho Koh iD, Chi-Hun Kim iD, Young Chul Youn iD, Dong Won Yang iD, Hyuk-Je Lee iD, Han Lee iD und 5 weitere

Journal of Clinical Neurology · 2025 · 21 (3) · 182

DOI: 10.3988/jcn.2024.0550 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Clinical Neurology, 2025. Verfasst von Sung Hoon Kang und 16 weiteren Autor:innen. Beteiligte Einrichtung: Department of Neurology, Korea University Guro Hospital, Korea University College of Medicine, Seoul, Korea. Die Arbeit wurde bisher 12-mal zitiert (Crossref) und nennt 20 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: National Research Council of Science and Technology (NST) Aging Convergence Research Center, Institute of Information and Communications Technology Planning and Evaluation, National Research Foundation of Korea.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND AND PURPOSE: We aimed to determine the proportion of Korean patients with early Alzheimer's disease (AD) who are eligible to receive lecanemab based on the United States Appropriate Use Recommendations (US AUR), and also identify the barriers to this treatment. METHODS: We retrospectively enrolled 6,132 patients with amnestic mild cognitive impairment or mild amnestic dementia at 13 hospitals from June 2023 to May 2024. Among them, 2,058 patients underwent amyloid positron emission tomography (PET) and 1,199 (58.3%) of these patients were amyloid-positive on PET. We excluded 732 patients who did not undergo brain magnetic resonance imaging between June 2023 and May 2024. Finally, 467 patients were included in the present study. RESULTS: When applying the criteria of the US AUR, approximately 50% of patients with early AD were eligible to receive lecanemab treatment. Among the 467 included patients, 36.8% did not meet the inclusion criterion of a Mini-Mental State Examination (MMSE) score of ≥22. CONCLUSIONS: Eligibility for lecanemab treatment was not restricted to Korean patients with early AD except for those with an MMSE score of ≥22. The MMSE criteria should therefore be reconsidered in areas with a higher proportion of older people, who tend to have lower levels of education.

Schlagwörter

Stichwörter der Autor:innen

Alzheimer's diseaseKoreanMini-Mental State Examinationeligibilitylecanemab

Autor:innen und Institutionen

  • Department of Neurology, Korea University Guro Hospital, Korea University College of Medicine, Seoul, Korea.
  • Department of Neurology, Ewha Womans University Seoul Hospital, Ewha Womans University College of Medicine, Seoul, Korea.
  • Department of Neurology, Soonchunhyang University Seoul Hospital, Soonchunhyang University College of Medicine, Seoul, Korea.
  • Department of Neurology, Ewha Womans University Mokdong Hospital, Ewha Womans University College of Medicine, Seoul, Korea.
  • Department of Neurology, Seoul National University Bundang Hospital, Seoul National University College of Medicine, Seongnam, Korea.
  • Department of Neurology, St. Vincent's Hospital, College of Medicine, The Catholic University of Korea, Suwon, Korea.

ORCID-Profile: Sung Hoon Kang, Jee Hyang Jeong, Jung-Min Pyun, Geon Ha Kim, Young Ho Park, YongSoo Shim, Seong-Ho Koh, Chi-Hun Kim, Young Chul Youn, Dong Won Yang, Hyuk-Je Lee, Han Lee, Dain Kim, Kyunghwa Sun, So Young Moon, Kee Hyung Park, Seong Hye Choi

Förderung

  • National Research Council of Science and Technology (NST) Aging Convergence Research Center
  • Institute of Information and Communications Technology Planning and Evaluation
  • National Research Foundation of Korea
  • Korea Dementia Research Center
  • Korea University

Zitieren

APA

Kang, S. H., Jeong, J. H., Pyun, J. M., Kim, G. H., Park, Y. H., Shim, Y., Koh, S. H., Kim, C. H., Youn, Y. C., Yang, D. W., Lee, H. J., Lee, H., Kim, D., Sun, K., Moon, S. Y., Park, K. H., & Choi, S. H. (2025). Eligibility for Lecanemab Treatment in the Republic of Korea: Real-World Data From Memory Clinics. Journal of Clinical Neurology, 21(3), 182. https://doi.org/10.3988/jcn.2024.0550

Vancouver

Kang SH, Jeong JH, Pyun JM, Kim GH, Park YH, Shim Y, et al. Eligibility for Lecanemab Treatment in the Republic of Korea: Real-World Data From Memory Clinics. Journal of Clinical Neurology. 2025;21(3):182. doi:10.3988/jcn.2024.0550

BibTeX
@article{Kang2025,
  author = {Kang, Sung Hoon and Jeong, Jee Hyang and Pyun, Jung-Min and Kim, Geon Ha and Park, Young Ho and Shim, YongSoo and Koh, Seong-Ho and Kim, Chi-Hun and Youn, Young Chul and Yang, Dong Won and Lee, Hyuk-Je and Lee, Han and Kim, Dain and Sun, Kyunghwa and Moon, So Young and Park, Kee Hyung and Choi, Seong Hye},
  title = {Eligibility for Lecanemab Treatment in the Republic of Korea: Real-World Data From Memory Clinics},
  journal = {Journal of Clinical Neurology},
  year = {2025},
  volume = {21},
  number = {3},
  pages = {182},
  doi = {10.3988/jcn.2024.0550}
}
Kostenlos starten →